Advertisement


Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

2025 ASCO Annual Meeting

Advertisement

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, with chemotherapy as a second-line treatment of patients with small cell lung cancer (SCLC) (LBA8008). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
DELPHI-304 trial is a randomized controlled phase 3 trial comparing tarlatamab to chemotherapy in the second-line treatment of patients with small cell lung cancer who had disease progression after first-line chemotherapy, with or without a checkpoint inhibitor. Tarlatamab is a bispecific T-cell engager that targets DLL3 and CD3 and was approved in the second-line treatment and beyond of advanced small cell lung cancer based on DELPHI-301, which showed a very good response rate. DELPHI-304, of which the results were reported by the investigators at the ASCO 2025 Annual Meeting, also had an associated manuscript published in the New England Journal of Medicine. The study showed impressive, significant improvement in overall survival—statistically significant and, more importantly, meaningful clinical improvements. The hazard ratio was 0.6. There was a median overall survival improvement of more than five months, from 8.3 to 11.6 months. Other clinical outcomes that were reported included a response rate of about 35%. There was also improvement in progression-free survival. Kudos also to the investigators who reported patient outcomes, and there was a significant improvement in patient symptoms, particularly dyspnea and cough, with tarlatamab. When it comes to safety profile, tarlatamab had overall a better safety profile. There were significantly fewer grade 3 or above adverse events compared to chemotherapy. When it comes to the unique side effects—CRS (cytokine release syndrome) and ICANS—they were mostly grade 1 or 2 and managed fairly well with minimal issues, except maybe one case of ICANS. Why is this study important? Very important, because it's the first study ever to show a drug that has a better overall survival benefit compared to chemotherapy in the second-line setting treatment of small cell lung cancer. This is a standard-of-care treatment. From now on, if not already, I will be using it in clinic. I'm already using it. A couple of things to make sure we address on this drug, tarlatamab. We do know that there are some logistics to administering the drug—maybe in the hospital for the first couple of doses, as was done initially in the trial, and then it was adjusted. The reason is to watch for those side effects. Although they're rare—the reactions, the CRS—it requires some extra time of observation after the infusion. But I think as we evolve, we're seeing that has been more doable, and the study itself showed that actually observing in outpatient is doable. And then of course, more importantly, even though the percentage of higher-grade adverse events was lower with tarlatamab, we still owe it to our patients to monitor closely, to optimize and do everything to support them, and to treat those in a timely manner.

Related Videos

Immunotherapy
Genomics/Genetics

Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy

Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504). 

Issues in Oncology

Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types

Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well as leukemia, lymphoma, and melanoma, from 2013 to 2022 (Abstract 11025). 

Breast Cancer

Sara M. Tolaney, MD, MPH, FASCO, on PD-L1–Positive Advanced TNBC: First-Line Doublet Comparison

Sara M. Tolaney, MD, MPH, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared sacituzumab govitecan-hziy plus pembrolizumab vs chemotherapy plus pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer (TNBC) (LBA109). 

 

Prostate Cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). 

 

Advertisement

Advertisement




Advertisement